This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clover Biopharmaceuticals Crescita futura

Future criteri di controllo 2/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Clover Biopharmaceuticals.

Informazioni chiave

n/a

Tasso di crescita degli utili

190.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	41.1%
Tasso di crescita dei ricavi	47.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	27 Jul 2023

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

SZSC:2197 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	2,341	N/A	N/A	N/A	1
12/31/2024	3,071	N/A	N/A	N/A	2
12/31/2023	2,571	N/A	N/A	N/A	2
6/30/2023	0	-665	N/A	N/A	N/A
3/31/2023	0	-1,559	N/A	N/A	N/A
12/31/2022	N/A	-2,452	-1,796	-1,691	N/A
9/30/2022	N/A	-4,145	-1,461	-1,356	N/A
6/30/2022	N/A	-5,838	-1,125	-1,021	N/A
3/31/2022	N/A	-5,927	-1,062	-969	N/A
12/31/2021	N/A	-6,016	-998	-918	N/A
12/31/2020	N/A	-913	363	477	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 2197 è superiore al tasso di risparmio ( 1.9% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 2197 cresceranno più velocemente del mercato Hong Kong

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 2197 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 2197 ( 47.9% all'anno) crescerà più rapidamente del mercato Hong Kong ( 7.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 2197 ( 47.9% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 2197 è previsto essere elevato tra 3 anni

This company listing is no longer active

Clover Biopharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Founder recently bought HK$1.2m worth of stock

CEO & Executive Director recently bought HK$595k worth of stock

New major risk - Financial position

Clover Biopharmaceuticals, Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Clover Biopharmaceuticals, Ltd. Provides Updates on Business and R&D Pipeline Development

Clover Biopharmaceuticals, Ltd. announced that it has received $48.882447 million in funding

Clover Launches Covid-19 Booster Vaccine in the People’s Republic of China

Clover Biopharmaceuticals, Ltd. Provides Updates on COVID-19 Vaccine Commercial Launch

Founder recently bought HK$1.0m worth of stock

Clover Biopharmaceuticals, Ltd. Announces COVID-19 Vaccine, SCB-2019 (CpG 1018/ Alum), Has Been Evaluated by Relevant Authorities of the People's Republic of China and Included for Emergency Use in the PRC

Clover Biopharmaceuticals, Ltd. Announces Vaccine Candidate Reduced Household Transmission of SARS-COV-2 by 84% in Study Published in Clinical Infectious Diseases

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Founder recently bought HK$636k worth of stock

Founder recently bought HK$421k worth of stock

Founder recently bought HK$1.2m worth of stock

Clover Biopharmaceuticals, Ltd.'s COVID-19 Vaccine Candidate Receives European Union GMP Certificate

Clover Biopharmaceuticals, Ltd. Announces Positive Data from Its Ongoing Phase 3 Study Evaluating IT’S SCB-2019

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd.’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5

Clover Announces Positive Phase 2/3 Results in Adolescents for Its Covid-19 Vaccine

Clover Biopharmaceuticals, Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Clover Biopharmaceuticals, Ltd. Announces Executive Changes

Clover Biopharmaceuticals, Ltd. Announces New Positive Clinical Data in Individuals Vaccinated with A Third Dose of Scb-2019 as A Homologous Booster Against the Omicron Variant

Clover Biopharmaceuticals, Ltd. Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors

Clover Biopharmaceuticals, Ltd. Doses First Patient with Scb-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 1 Trial with SCB-2020S, Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Clover Biopharmaceuticals, Ltd., Annual General Meeting, May 27, 2022

High number of new and inexperienced directors

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita